IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0510651
(2009-07-28)
|
등록번호 |
US-8203029
(2012-06-19)
|
발명자
/ 주소 |
- Gibbins, Bruce L.
- Hopman, Lance D.
|
출원인 / 주소 |
- Kimberly-Clark Worldwide, Inc.
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
5 인용 특허 :
136 |
초록
▼
The present invention comprises methods and compositions for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compositions for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a n
The present invention comprises methods and compositions for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compositions for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses.
대표청구항
▼
1. A biocompatible antimicrobial matrix, comprising a hydrophilic cross-linked polymer network and a metal colloid incorporated in the matrix, wherein the metal colloid is formed by the direct reaction of an anion and a metal cation, and wherein the anion is in an excess concentration of the metal c
1. A biocompatible antimicrobial matrix, comprising a hydrophilic cross-linked polymer network and a metal colloid incorporated in the matrix, wherein the metal colloid is formed by the direct reaction of an anion and a metal cation, and wherein the anion is in an excess concentration of the metal cation, such that association of the metal cation and the anion is favored. 2. The matrix of claim 1, further comprising one or more active agents. 3. The matrix of claim 2, wherein the one or more active agents are antimicrobial agents, antifungal agents, antibacterial agents, anti-viral agents, antiparasitic agents, anaesthetics, mucopolysaccharides, growth factors, proteins, angiogenic factors, wound healing agents, or adjuvants. 4. The matrix of claim 3, wherein the antimicrobial agents are isoniazid, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, sparfloxacin, rifampin, azithromycin, clarithromycin, dapsone, tetracycline, erythromycin, ciprofloxacin, doxycycline, ampicillin, amphotericin B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycin, diclazanl, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, miconazole, Zn-pyrithione, bromide, iodide or periodate. 5. The matrix of claim 1, wherein the hydrophilic cross-linked polymer is polyacrylamide. 6. The matrix of claim 3, wherein the mucopolysaccharides are heparin, heparin sulfate, heparinoids, dermatan sulfate, pentosan polysulfate, chondroitin sulfate, hyaluronic acid, cellulose, agarose, chitin, dextran, carrageenin, linoleic acid, or allantoin. 7. The matrix of claim 3, wherein the growth factors are basic fibroblast growth factor, acidic fibroblast growth factor, nerve growth factor, epidermal growth factor, insulin-like growth factors 1 and 2, platelet derived growth factor, tumor angiogenesis factor, vascular endothelial growth factor, corticotropin releasing factor, transforming growth factors alpha and beta, interleukin-8, granulocyte-macrophage colony stimulating factor, interleukins, or interferons. 8. The matrix of claim 3, wherein the proteins are collagen, cross-linked collagen, fibronectin, laminin, elastin, cross-linked elastin, antibodies, or combination or fragments thereof. 9. The matrix of claim 1, further comprising a non-gellable polysaccharide. 10. The matrix of claim 9, wherein the non-gellable polysaccharide is guar gum, lucerne, fenugreek, honey locust bean gum, white clover bean gum, or carob locust bean gum. 11. The matrix of claim 10, wherein the non-gellable polysaccharide is guar gum. 12. The matrix of claim 1, further comprising an electron acceptor. 13. The matrix of claim 12, wherein the electron acceptor is cupric chloride, ferric chloride, gold, platinum, or cesium. 14. The matrix of claim 1, wherein the metal cation is silver. 15. The matrix of claim 1, wherein the metal colloid is a weakly soluble silver chloride colloid. 16. The matrix of claim 1, further comprising a water loss control agent, a plasticizer, or a hydration control agent. 17. A wound care device comprising an antimicrobial cross-linked hydrophilic polymer network, and a metal colloid directly incorporated in the network, wherein the metal colloid is formed by the reaction of an anion and a metal cation, and wherein the anion is in an excess concentration of the metal cation, such that association of the metal cation and the anion is favored. 18. The device of claim 17, wherein the cross-linked hydrophilic polymer network is polyacrylamide. 19. A biocompatible antimicrobial matrix, comprising a hydrophilic cross-linked polyacrylamide polymer network, a non-gellable polysaccharide, and a silver chloride colloid incorporated in the matrix, wherein the silver chloride colloid is formed by the direct reaction of a chloride anion and a silver cation, and wherein the chloride anion is in an excess concentration of the silver cation, such that association of the silver cation and the chloride anion is favored. 20. The matrix of claim 19, further comprising an electron acceptor. 21. The matrix of claim 19, further comprising a water loss control agent, a plasticizer, or a hydration control agent. 22. The matrix of claim 19, further comprising an active agent.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.